Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward

Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene–environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities for prevention, early diagnosis, and intervention. To advance these concepts, we propose therapeutic trials in two major groups of subjects: “young” individuals with COPD and those with pre-COPD. Given that lungs grow to about 20 years of age and begin to age at approximately 50 years, we consider “young” patients with COPD those patients in the age range of 20–50 years. Pre-COPD relates to individuals of any age who have respiratory symptoms with or without structural and/or functional abnormalities, in the absence of airflow limitation, and who may develop persistent airflow limitation over time.

Puedes leer el artículo completo aquí: https://www.atsjournals.org/doi/full/10.1164/rccm.202107-1663SO

Autores: Fernando J. Martinez, Alvar Agusti, Bartolome R. Celli, MeiLan K. Han, James P. Allinson, Surya P. Bhatt, Peter Calverley, Sanjay H. Chotirmall, Badrul Chowdhury, Patrick Darken, Carla A. Da Silva, Gavin Donaldson, Paul Dorinsky, Mark Dransfield, Rosa Faner, David M. Halpin, Paul Jones, Jerry A. Krishnan, Nicholas Locantore, Fernando D. Martinez, Hana Mullerova, David Price, Klaus F. Rabe, Colin Reisner, Dave Singh, Jørgen Vestbo, Claus F. Vogelmeier, Robert A. Wise, Ruth Tal-Singer, and Jadwiga A. Wedzicha.